Thomas Stauch: ITP Therapeutics Enter a New Era of Targeted Treatment
Thomas Stauch, Founder of Hematology and Oncology Practice in Jena, Consultant Physician at Jena University Hospital, shared a post on LinkedIn:
“Always great to listen to David Kuter speaking about ITP.
His work has shaped our understanding of immune thrombocytopenia for decades and has influenced the care of countless patients worldwide.
At EHA 2026, Prof. Kuter presented the final long-term extension results of the LUNA 3 study evaluating rilzabrutinib in persistent and chronic ITP.
Beyond the data itself, it is inspiring to see a true pioneer continue to drive innovation and challenge our thinking in a field that has evolved tremendously over the last years.
From corticosteroids and splenectomy to TPO receptor agonists, SYK inhibition, BTK inhibition, FcRn blockade, complement inhibition, and emerging immune-modulating approaches, the therapeutic landscape of ITP has never been more dynamic.
Much of this progress has been accompanied, influenced, or inspired by leaders such as Prof. Kuter.
Thank you for your lifelong dedication to advancing ITP research and improving the lives of our patients.”
Stay updated with Hemostasis Today.
-
Jul 29, 2026, 17:41Seema Dawood: Difference Between CBC Smear Staining and Cell Counts Staining
-
Jul 29, 2026, 16:30Mostafa Faisal: Impact of DNMT3A and TET2 Mutations on Clotting and Bleeding in PV and ET
-
Jul 29, 2026, 16:01Gerardo Moscatelli: The Spike Protein Cascade – From Endothelial Binding to Vascular Collapse
-
Jul 29, 2026, 15:42Julie Cardoso: FDA Clears the First AI-Guided Ultrasound Software for Suspected DVT
-
Jul 29, 2026, 15:26Ahmad Alkhammash: Completing an Advanced Fellowship in Adult Thrombosis Medicine
-
Jul 29, 2026, 15:13Yara Mahmoud: The Molecular Basis in Hematology
-
Jul 29, 2026, 15:11Louisa Jorm: A New Era of Dynamic Cardiovascular Risk Assessment
-
Jul 29, 2026, 15:04Filippo Consonni: Treatment Strategies for Hematologic Immune Dysregulation in Inborn Errors of Immunity
-
Jul 29, 2026, 14:53Samer Alsaid: Warfarin Outcomes Reassessed Through COMBINE AF